<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">TIH</journal-id>
<journal-id journal-id-type="hwp">sptih</journal-id>
<journal-id journal-id-type="nlm-ta">Toxicol Ind Health</journal-id>
<journal-title>Toxicology and Industrial Health</journal-title>
<issn pub-type="ppub">0748-2337</issn>
<issn pub-type="epub">1477-0393</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0748233711416946</article-id>
<article-id pub-id-type="publisher-id">10.1177_0748233711416946</article-id>
<title-group>
<article-title>Nanoencapsulated and microencapsulated enzymes in drug antidotal therapy</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Szilasi</surname>
<given-names>Mária</given-names>
</name>
<xref ref-type="aff" rid="aff1-0748233711416946">1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Budai</surname>
<given-names>Marianna</given-names>
</name>
<xref ref-type="aff" rid="aff2-0748233711416946">2</xref>
<xref ref-type="aff" rid="aff3-0748233711416946">3</xref>
<xref ref-type="corresp" rid="corresp1-0748233711416946"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Budai</surname>
<given-names>Lívia</given-names>
</name>
<xref ref-type="aff" rid="aff2-0748233711416946">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Petrikovics</surname>
<given-names>Ilona</given-names>
</name>
<xref ref-type="aff" rid="aff3-0748233711416946">3</xref>
</contrib>
</contrib-group>
<aff id="aff1-0748233711416946"><label>1</label>Department of Pulmonology, Medical and Health Science Center, University of Debrecen, Debrecen, Hungary</aff>
<aff id="aff2-0748233711416946"><label>2</label>Department of Pharmaceutics, Semmelweis University, Budapest, Hungary</aff>
<aff id="aff3-0748233711416946"><label>3</label>Department of Chemistry, Sam Houston State University, Huntsville, TX, USA</aff>
<author-notes>
<corresp id="corresp1-0748233711416946">Marianna Budai, Department of Chemistry, Sam Houston State University, Box 2117, Huntsville, TX 77341, USA Email: <email>bmariann@gyok.sote.hu</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>7</month>
<year>2012</year>
</pub-date>
<volume>28</volume>
<issue>6</issue>
<fpage>522</fpage>
<lpage>531</lpage>
<permissions>
<copyright-statement>© The Author(s) 2011</copyright-statement>
<copyright-year>2011</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>A catalytic bioscavenger for the therapeutic and prophylactic defense against recognized chemical threat agents has been a long-standing objective of civilian and military research. Among the toxic agents, organophosphate molecules and cyanide have been widely studied. In order to overcome the limitations of traditional antidotal therapies, isolated, purified, recombinant enzymes with bacterial origin possessing fast catalytic activity were used in <italic>in vitro</italic> and <italic>in vivo</italic> experiments. However, the fast degradation, excretion and adverse immunologic reaction against enzymes limit their <italic>in vivo</italic> use. Development of biodegradable, nontoxic carrier systems, microparticles, and nanoparticles—offering advantageous pharmacokinetic parameters was suggested. Present work deals with the perspectives of carrier systems, such as resealed and annealed erythrocytes and sterically stabilized liposomes. Dendritic polymers and polymer-conjugated enzymes, being in the focus of extensive research efforts nowadays, are also discussed.</p>
</abstract>
<kwd-group>
<kwd>Organophosphate</kwd>
<kwd>cyanide</kwd>
<kwd>antagonism</kwd>
<kwd>antidotal enzyme</kwd>
<kwd>sterically stabilized liposome</kwd>
<kwd>dendrimer</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0748233711416946">
<title>Poisoning caused by organophosphorus molecules</title>
<p>In the 20th century, a large number of neurotoxic organophosphate (OP) compounds have been synthesized for use as agricultural pesticides or chemical warfare agents. Phosphotriesters, phosphothiol esters, and phosphorothiolates (e.g. parathion, malathion) have been used to control insects and pests. Some of the phosphofluoridates and phosphothioates (e.g. soman, sarin) are extremely toxic cholinergic inhibitors and have been stockpiled as chemical warfare agents (<xref ref-type="bibr" rid="bibr13-0748233711416946">Cheng et al., 2004</xref>).</p>
<p>The OP molecules exhibit their toxic effects in humans by irreversible inhibition of the enzyme acetylcholinesterase (AChE). This results in the accumulation of the neurotransmitter, acetylcholine, resulting in the overstimulation of the effector cells and cholinergic intoxication.</p>
<p>Nowadays, the combination of atropine, an acetylcholine receptor antagonist, and the AChE reactivator, pralidoxime (2-PAM), is the most commonly used antidotal combination to treat OP poisoning. Although these conventional regimens have been demonstrated to show increased survival in model animals, they do not destroy (biotransform) the OP molecules in the body. In recent years, enzymes—that chemically destroy (biotransform) the OP molecules in the body—have been used for enhanced protection against chemical warfare agents. Hydrolytic enzymes, such as organophosphorus hydrolase (OPH) and organophosphorus acid anhydrolase (OPAA), isolated from bacteria have been extensively developed in the past decade. Since catalytic OPH and OPAA are highly efficient and can detoxify many times agents of their own weight in seconds or minutes (<xref ref-type="bibr" rid="bibr13-0748233711416946">Cheng et al., 2004</xref>). Administration of exogenous human butyrylcholinesterase (huBChE) has also been studied to antagonize OP intoxication (<xref ref-type="bibr" rid="bibr7-0748233711416946">Broomfield et al., 1991</xref>; <xref ref-type="bibr" rid="bibr11-0748233711416946">Cerasoli et al., 2005</xref>; <xref ref-type="bibr" rid="bibr24-0748233711416946">Lenz et al., 2007</xref>). The huBChE irreversibly binds to OP agents to prevent inactivation of AChE and it has been proved to serve as a potential strategy for preventing OP toxicity (<xref ref-type="bibr" rid="bibr24-0748233711416946">Lenz et al., 2007</xref>). The huBChE has a broad spectrum of activity, relatively long half-life and limited physiological side effects. However, as 1:1 stochiometry is required for protection against OP agents (<xref ref-type="bibr" rid="bibr42-0748233711416946">Raveh et al., 1997</xref>), large quantities of huBChE are needed for effective treatment and prophylaxis. Recombinant BChE (rBChE) has been expressed in <italic>Escherichia coli</italic> (<xref ref-type="bibr" rid="bibr28-0748233711416946">Masson et al., 1990</xref>). However, the expression systems cannot economically produce sufficient quantities of rBChE with the same characteristics similar to the huBChE. The production of rBChE was published by <xref ref-type="bibr" rid="bibr20-0748233711416946">Huang et al. (2007)</xref>. Research on paraoxonase (PON), a multigene family, has risen in the last decade (<xref ref-type="bibr" rid="bibr19-0748233711416946">Furlong et al., 1991</xref>; <xref ref-type="bibr" rid="bibr23-0748233711416946">La Du, 2002</xref>). Within the PON family, three enzyme groups (PON1, PON2, PON3) have been identified and declared to have important roles in the development of various diseases such as cardiovascular, rheumatic arthritis, Alzheimer’s, and diabetes mellitus. Specific enzyme activities of purified recombinant human PONs have been reported by <xref ref-type="bibr" rid="bibr17-0748233711416946">Draganov et al. (2005)</xref>. Hydrolysis of certain OP molecules (diazoxon, chlorpyrifos oxon) has been declared to be physiologically important, while hydrolyzis of paraoxon (PO) has much less physiological importance, but it has potential toxicological importance (<xref ref-type="bibr" rid="bibr27-0748233711416946">Li et al., 2000</xref>). The PON1 also has important roles in lipid metabolism (<xref ref-type="bibr" rid="bibr15-0748233711416946">Deakin and James, 2004</xref>). The ability of human PON1 to hydrolyze a variety of substrates, including OP nerve agents in a catalytic manner enables it to be considered a potential bioscavenger of chemical warfare agents. However, the wild-type natural form of human PON1 does not have sufficient catalytic activity to act as a bioscavenger. Research efforts are focusing on developing more viable mutants of PON1 with enhanced kinetic activity for deactivating the OP nerve agents, which can provide <italic>in vivo</italic> protection against nerve agents. Studying the active centra and the binding mechanism of PON1 suggests that although this is a promiscuous enzyme and has potential to be used in externally administered enzyme therapy, there are substantial constraints in the active site pocket, which may relate to both the leaving group and the retained portion of PO analogues (<xref ref-type="bibr" rid="bibr44-0748233711416946">Sanan et al., 2010</xref>).</p>
</sec>
<sec id="section2-0748233711416946">
<title>Poisoning caused by cyanide</title>
<p>Although the first cyanide (CN) poisoning was reported in 1679—from bitter almond—the exact biochemical mechanism of action was described in 1933. The specific treatment of CN intoxication means the use of scavengers (e.g. methemoglobin former sodium nitrite [SN] or cobalt compounds or cyanohydrin formers) and/or the conversion of CN into the less toxic thiocyanate (SCN<sup>–</sup>) with exogenously administered sulfane sulfur and sulfurtransferase enzymes (<xref ref-type="bibr" rid="bibr29-0748233711416946">McGuinn et al., 1994</xref>; <xref ref-type="bibr" rid="bibr48-0748233711416946">Way, 1983</xref>, <xref ref-type="bibr" rid="bibr49-0748233711416946">1984</xref>). Sulfurtransferases are specialized carrier proteins that transport the sulfur to various acceptors, while forming a stable protein–sulfur complex. They catalyze the transfer of a sulfane sulfur atom from a donor molecule to a thiophilic acceptor substrate, such as CN. Rhodanese (Rh) is the best characterized multifunctional, mitochondrial sulfurtransferase (<xref ref-type="bibr" rid="bibr6-0748233711416946">Bordo et al., 2000</xref>; <xref ref-type="bibr" rid="bibr16-0748233711416946">Dooley et al., 1995</xref>; <xref ref-type="bibr" rid="bibr43-0748233711416946">Saidu, 2004</xref>).</p>
<p>Extensive researches were focused on sulfur-containing compounds too. Thiosulfate (TS) was first sulfur compound found to participate in the enzyme reaction. The TS therefore could be used as a CN antidote, but it has only limited ability to reach the enzyme because of a nearly exclusive extracellular distribution. <xref ref-type="bibr" rid="bibr5-0748233711416946">Baskin et al. (1999)</xref> reported the <italic>in vitro</italic> and <italic>in vivo</italic> efficacy of various sulfur donors with various chemical structures. All test compounds (e.g. 3-hydroxypyridin-2-yl N-[(N-methyl-3-aminopropyl)]-2-aminoethyl disulfide dihydrochloride or diisopropyl tetrasulfide) showed greater lipophilicity than the classical inorganic TS. Their ability to protect mice against two LD<sub>50</sub> of sodium cyanide administered either 15 or 60 min following the administration of a sulfur donor was assessed. These tests demonstrated that altering the chemical substituent of the longer chain sulfide modified the ability of the candidate molecule to protect against CN toxicity. At least two of the selected sulfur donors provided 100% protection against two LD<sub>50</sub> of sodium cyanide.</p>
</sec>
<sec id="section3-0748233711416946">
<title>Application of free antidotal enzymes</title>
<p>Earlier investigations were focused on the administration of free Rh and TS directly to the blood stream (<xref ref-type="bibr" rid="bibr18-0748233711416946">Frankenberg, 1980</xref>). Given therapeutically to mice after symptoms of CN poisoning developed, Rh and a sulfur donor provided good antidotal effect. With increasing time interval between the injection of Rh plus TS and CN, the prophylactic antidotal effect of TS rapidly decreased. The Rh enzyme activity in plasma decreased rapidly after intravenous injection of Rh, and the Rh activity was detected in the urine soon after the injection. It seemed, however, unlikely that renal excretion alone was responsible for the rapid Rh elimination from the blood; tissue uptake could as well occur (<xref ref-type="bibr" rid="bibr18-0748233711416946">Frankenberg, 1980</xref>).</p>
<p>Similarly, recombinant OPH enzyme has also been employed to rapidly hydrolyze the toxic OP compounds and protect against OP intoxication in animal models (<xref ref-type="bibr" rid="bibr2-0748233711416946">Ashani et al., 1991</xref>; <xref ref-type="bibr" rid="bibr8-0748233711416946">Broomfield, 1992</xref>).</p>
<p>However, the free enzymes were rapidly destroyed by the body’s immune system; therefore, the efficacy of this approach—using free, unprotected enzymes—was quite limited.</p>
</sec>
<sec id="section4-0748233711416946">
<title>Carrier systems</title>
<p>To protect the highly purified recombinant metabolizing enzymes from various adverse disposition factors and minimize the potential immunologic reactions in the circulation, appropriate enzyme carriers needed to be developed (<xref ref-type="bibr" rid="bibr32-0748233711416946">Pei et al., 1994</xref>; <xref ref-type="bibr" rid="bibr49-0748233711416946">Way, 1984</xref>). Basically, the right carrier system should provide a long-lasting, high enzyme activity in the circulation. Requirements for an ideal carrier system are to be resistant to the attack of the immune system, permeable for the toxin molecules, biocompatible, and to possess high encapsulation efficiency with no toxic effects, and to show a predictable degradation kinetic (<xref ref-type="fig" rid="fig1-0748233711416946">Figure 1</xref>
).</p>
<fig id="fig1-0748233711416946" position="float">
<label>Figure 1.</label>
<caption>
<p>Mechanism of action in case of encapsulated antidotal enzymes.</p>
</caption>
<graphic xlink:href="10.1177_0748233711416946-fig1.tif"/>
</fig>
<p>To develop carrier systems, microparticles and nanoparticles can be utilized. Among microparticles, first the resealed and annealed erythrocytes—possessing some micrometer diameter—were extensively studied (<xref ref-type="bibr" rid="bibr51-0748233711416946">Way et al., 1985</xref>). Later on, small unilamellar liposomes of ˜100–150 nm diameter were in the focus of encapsulation efforts. Nowadays, dendritic polymers (DPs) of some nanometer size offer excellent opportunity for capturing enzymes. Furthermore, the conjugation of antidotal enzymes with polyethylene glycol (PEG) is also a promising method in order to achieve advantageous pharmacokinetic parameters in the antidotal therapy.</p>
</sec>
<sec id="section5-0748233711416946">
<title>Carrier erythrocytes</title>
<p>The first investigation efforts for overcoming the limitations of the potential therapeutic value of such free enzymes as antidotes were based on Ihler’s ideas and results. <xref ref-type="bibr" rid="bibr21-0748233711416946">Ihler et al. (1973)</xref> first reported that enzymes can be successfully entrapped within resealed and annealed erythrocytes, carrier red blood cells (CRBCs), by hypotonic dialysis.</p>
<p>Representing the mentioned approach, CRBCs encapsulating bovine Rh were employed in CN antagonism with success (<xref ref-type="fig" rid="fig2-0748233711416946">Figure 2</xref>
; <xref ref-type="bibr" rid="bibr10-0748233711416946">Cannon et al., 1994</xref>; <xref ref-type="bibr" rid="bibr25-0748233711416946">Leung et al., 1991a</xref>, <xref ref-type="bibr" rid="bibr26-0748233711416946">1991b</xref>; <xref ref-type="bibr" rid="bibr39-0748233711416946">Petrikovics et al., 1994</xref>; <xref ref-type="bibr" rid="bibr51-0748233711416946">Way et al., 1985</xref>, <xref ref-type="bibr" rid="bibr50-0748233711416946">1991</xref>). According to <xref ref-type="bibr" rid="bibr26-0748233711416946">Leung et al. (1991b)</xref>, when a 10-mg/kg dose of potassium cyanide was administered subcutaneously, only 37.5% of the mice survived; whereas when animals were pretreated with 1.71 units of Rh and 1 mM sodium thiosulfate 24 h prior to challenge with CN, all the animals survived. However, the approach was limited by the use of inorganic TS, which does not diffuse easily through cell membranes, and product inhibition of Rh can occur due to inorganic sulfite accumulation (<xref ref-type="bibr" rid="bibr36-0748233711416946">Petrikovics et al., 1995</xref>). Other sulfur donors possessing better lipid solubility can penetrate cell membranes, and as a consequence of it, can serve as a better substrate for Rh. When murine CRBCs containing bovine liver Rh was administered intravenously into Balb/C mice with combination of the sulfur donors, such as butanethiosulfonate or TS prior to potassium cyanide, the CRBC-butanethiosulfonate system showed significantly enhanced protection over that of CRBC-TS system (<xref ref-type="bibr" rid="bibr36-0748233711416946">Petrikovics et al., 1995</xref>).</p>
<fig id="fig2-0748233711416946" position="float">
<label>Figure 2.</label>
<caption>
<p>Main preparation steps of loaded erythrocytes.</p>
</caption>
<graphic xlink:href="10.1177_0748233711416946-fig2.tif"/>
</fig>
<p>The new conceptual approach using resealed carrier erythrocytes containing a recombinant enzyme was employed to antagonize OP intoxication too (<xref ref-type="bibr" rid="bibr52-0748233711416946">Way et al., 1997</xref>). Incorporation of phosphotriesterase within resealed murine erythrocytes was accomplished by hypotonic dialysis. The properties of this enzyme within these resealed erythrocytes were investigated. The <italic>in vitro</italic> studies suggested that carrier erythrocytes might be developed as an approach for the prophylactic and therapeutic antagonism of organophosphorus intoxication (<xref ref-type="bibr" rid="bibr32-0748233711416946">Pei et al., 1994</xref>). Evaluating the <italic>in vivo</italic> efficacy of the mentioned system it could be concluded that annealed murine erythrocytes containing the recombinant phosphotriesterase provided striking protection against the lethal effect of PO, an active metabolite of an agricultural pesticide, parathion. The carrier cells were administered to mice either alone or in combination with 2-PAM and/or atropine. In case of the recipient mice, protection of free enzyme and encapsulated enzyme was compared and the encapsulated enzyme was found to persist longer and possess much greater antidotal efficacy. The results indicated that the erythrocyte carrier alone was quite effective in the antagonism of organophosphorus intoxication. Moreover, when these carrier cells were administered in combination with 2-PAM and/or atropine, a marked synergism was observed (<xref ref-type="bibr" rid="bibr33-0748233711416946">Pei et al., 1995</xref>).</p>
<p>Although CRBCs have an advantage of long circulation time (in human 92 days), they are not considered as a practical carrier system, as prior blood typing is necessary, they are fragile cells and sophisticated encapsulation technique is needed (<xref ref-type="fig" rid="fig2-0748233711416946">Figure 2</xref>; <xref ref-type="bibr" rid="bibr26-0748233711416946">Leung et al., 1991b</xref>).</p>
</sec>
<sec id="section6-0748233711416946">
<title>Liposomal systems with prolonged circulation time</title>
<p>One approach for partly overcoming the limitations of free bacterial enzymes is to encapsulate them within a bioprotective environment, for example sterically stabilized long-circulating liposomes (SL). Liposomes, as artificially prepared vesicles made of one or more lipid bilayer or bilayers are composed of naturally derived phospholipids, with mixed lipid chains and cholesterol. Although liposomes were first described by <xref ref-type="bibr" rid="bibr3-0748233711416946">Bangham in 60s (1963)</xref>, research efforts with PEG chains and sterically stabilized liposomes were carried out only later (<xref ref-type="bibr" rid="bibr31-0748233711416946">Papahadjopoulos et al., 1991</xref>). According to <xref ref-type="bibr" rid="bibr4-0748233711416946">Barenholz (2001)</xref>, one of the three major achievements of liposome application is the steric stabilization. PEGylated lipid, 2–5%, was used for liposome preparation in order to ensure steric hindrance during storage and longer half-life in the blood circulation due to the reduced recognition by the immune system.</p>
<p>The molecular interactions between the carrier system and the encapsulated enzyme have an impact on the <italic>in vitro</italic> stability and <italic>in vivo</italic> fate of the enzyme carrier system; therefore, it is of importance to determine selected physicochemical parameters to characterize the enzyme-containing liposomes, with special consideration of the requirements for intravenous administration (<xref ref-type="bibr" rid="bibr9-0748233711416946">Budai et al., 2009</xref>; <xref ref-type="bibr" rid="bibr35-0748233711416946">Petrikovics et al., 2009</xref>). To ensure a relatively high encapsulation efficiency and stability for OPH or Rh encapsulation, optimal lipid compositions for sterically stabilized liposomes were determined (<xref ref-type="fig" rid="fig3-0748233711416946">Figure 3</xref>
). The encapsulation efficiency and its time stability can be determined after separating the encapsulated and free enzyme fractions by gel filtration. The fluidity of the liposomal membrane and its alteration due to the encapsulated enzyme or temperature can be characterized by electron spin resonance spectroscopy (ESR). As liposomal enzymes are prepared for intravenous administration, osmolarity, pH, and size distribution of vesicular systems should fulfill the special requirements of the parenteral dosage forms. Physiologic pH and osmolarity can be reached using an appropriate buffer system. The vesicles were prepared by thin-film-hydration technique followed by extrusion through polycarbonate filters with defined pore size. In order to avoid any thrombosis-related side effects, the mean size of vesicles possessing homogeneous size distribution should be less than ˜200 nm. According to literature data, the optimal lipid composition—for encapsulation of the antidotal enzymes examined—consists of 56.9 mol% 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 38.0 mol% cholesterol, and 5.1 mol% 1,2-dipalmitoyl-sn-glycero- 3-phosphoethanolamine-<italic>N</italic>-[methoxy(polyethylene glycol)-2000] ammonium salt (<xref ref-type="bibr" rid="bibr9-0748233711416946">Budai et al., 2009</xref>; <xref ref-type="bibr" rid="bibr35-0748233711416946">Petrikovics et al., 2009</xref>).</p>
<fig id="fig3-0748233711416946" position="float">
<label>Figure 3.</label>
<caption>
<p>Main preparation steps of sterically stabilized, antidotal enzyme containing liposomes.</p>
</caption>
<graphic xlink:href="10.1177_0748233711416946-fig3.tif"/>
</fig>
<p>
<italic>In vivo</italic> effects of liposomal enzymes were also tested: the OPH or OPAA encapsulated in SL were injected into Balb/C mice 1 hour prior to exposing the animals with PO or diisopropylfluorophosphate (DFP), respectively (<xref ref-type="bibr" rid="bibr38-0748233711416946">Petrikovics et al., 1999</xref>, <xref ref-type="bibr" rid="bibr37-0748233711416946">2000a</xref>, <xref ref-type="bibr" rid="bibr40-0748233711416946">2000b</xref>). Enzymes encapsulated within liposomes provided increased protection to mice. Without any treatment, the LD<sub>50</sub> was found to be 1–4 mg/kg for OP agents examined. The traditional therapeutic protocol, using the combination of atropine + 2-PAM resulted in 29–55 mg/kg LD<sub>50</sub>. For liposomal-encapsulated OPAA against DFP and OPH against PO, the LD<sub>50</sub> values were 9.6 and 125, respectively. The combination of encapsulated enzymes and atropine + 2-PAM led to significantly increased LD<sub>50s</sub>, for SL-OPAA + atropine + 2-PAM against DFP 98.6 mg/kg, while for SL-OPH + atropine + 2-PAM against PO 920 mg/kg LD<sub>50</sub> values were determined. In summary, the encapsulation of OPH or OPAA into sterically stabilized, long-circulating liposomes increased the enzymes’ efficacy <italic>in vivo</italic> (<xref ref-type="bibr" rid="bibr38-0748233711416946">Petrikovics et al., 1999</xref>, <xref ref-type="bibr" rid="bibr37-0748233711416946">2000a</xref>, <xref ref-type="bibr" rid="bibr40-0748233711416946">2000b</xref>). The results indicate that the liposomal carrier system provided an enhanced protective effect against the OP compounds and the associated toxicity and lethality. Moreover, when these carrier liposomes were administered with 2-PAM and/or atropine, a dramatic enhanced protection was observed (<xref ref-type="bibr" rid="bibr38-0748233711416946">Petrikovics et al., 1999</xref>, <xref ref-type="bibr" rid="bibr37-0748233711416946">2000a</xref>, <xref ref-type="bibr" rid="bibr40-0748233711416946">2000b</xref>).</p>
</sec>
<sec id="section7-0748233711416946">
<title>Application of DPs</title>
<p>The application of DPs, a nanocapsule, polyoxazoline-based hyperbranched polymer with a C18 surface modifier, was first reported in the mid-80s (<xref ref-type="bibr" rid="bibr45-0748233711416946">Tomalia et al., 1985</xref>). Their application as drug carrier rapidly gained favor, primarily due to their inertness to temperature changes, solvent, and pH extremes (<xref ref-type="bibr" rid="bibr46-0748233711416946">Tomalia and Esfand, 1997</xref>).</p>
<p>The synthetic work for the hyperbranched poly (2-ethyloxazoline) with a CH<sub>3</sub>(CH<sub>2</sub>)<sub>17</sub> chain-modified surface can be performed as reported by <xref ref-type="bibr" rid="bibr53-0748233711416946">Xia et al. (2002)</xref> and <xref ref-type="bibr" rid="bibr54-0748233711416946">Yin et al. (1997)</xref>. The dendrimer is referred to as C<sub>18</sub>-HBP<sub>20/100</sub>, where the subscript 20/100 represents the average number of repeat units for interior branches and the center core molecule (i.e. 20 and 100 repeat units, respectively). The DP can be dissolved in appropriate aqueous buffers and then combined with the aqueous system of the enzyme to make up the final concentration of ˜10 mg/ml dendrimer–enzyme mixture with a ratio of polymer to enzyme of ˜10:1 (weight-by-weight [w/w]). The size distribution measurements for the DP-nanodevices demonstrated that the presence of Rh enzyme leads to an increase in the average size of the DP-particles. In the enzyme-free DP sample, the most common hydrodynamic radius is 4.9 nm and a second peak of 85.6 nm can also be observed. For the Rh-treated DP, the peaks were shifted toward higher values, indicating that the presence of the enzyme causes the formation of a network between the dendrimer units (<xref ref-type="bibr" rid="bibr34-0748233711416946">Petrikovics et al., 2010</xref>).</p>
<p>The OPAA and OPH enzymes were encapsulated into dendritic nanostructures (DP-OPAA and DP-OPH) too. As OP substrates DFP and PO were applied and tested, respectively. The <italic>in vivo</italic> efficacies of the antidotal systems were expressed as antidotal potency ratio (APR), representing the ratio of LD<sub>50 (mean)</sub> of the toxin with antagonists and LD<sub>50 (mean)</sub> of the toxin without antagonists. The DP-OPH alone provides a 95.5 × LD<sub>50</sub> protection against PO, while DP-OPPA demonstrates a more modest 2.7 × LD<sub>50</sub> protection against DFP. The DP-OPH alone provides better protection against PO than the traditional therapies of 2-PAM (˜20×) or atropine (˜40×). Although the <italic>in vivo</italic> efficacy of the DP-OPH system is approximately 30× greater than that of the DP-OPAA (alone or in combination with 2-PAM and atropine), both the DP enzymatic systems synergistically enhance the traditional 2-PAM + atropine combination therapy (APR values for DP-OPH or DP-OPAA systems in combination with 2-PAM + atropine are about 800 and 24, respectively; <xref ref-type="bibr" rid="bibr41-0748233711416946">Petrikovics et al., 2007</xref>).</p>
<p>Studies evaluating the <italic>in vitro</italic> and <italic>in vivo</italic> prophylactic efficacy of nanointercalated Rh in the presence of the classic inorganic sodium TS and a chemical component of garlic, diallyldisulfide (DADS), were also performed (<xref ref-type="bibr" rid="bibr34-0748233711416946">Petrikovics et al., 2010</xref>).</p>
<p>The APR is the ratio of the average LD<sub>50</sub> of CN with and without antagonists. The control mice were exposed to CN without antagonists or enzymes. The control APR is 1, by definition.</p>
<p>Based on these studies, it can be concluded that DADS itself is not a promising sulfur donor candidate. It reacts nonenzymatically with CN at the same rate as TS; but in the presence of Rh, TS reacts seven times faster than DADS. Administration of nanointercalated Rh doubled the protection of TS alone (relative APR = 2.22). The protection was also significantly enhanced when TS was employed in combination with the methemoglobin former SN (relative APR = 1.4). TS provided twice as much antidotal protection as DADS when applied with nanointercalated Rh alone (sulfur donor + DP-Rh) and also when the sulfur donors were combined with SN and externally administered nanointercalated Rh (sulfur donor + SN + DP-Rh). Nanocaptured Rh significantly enhanced the prophylactic antidotal protection with TS alone and in combination with SN. The prophylactic <italic>in vivo</italic> efficacy studies with TS and DADS indicate a parallel behavior in the body to their <italic>in</italic>
<italic>vitro</italic> activity. The maximum protection achieved with this system was about 10 times the LD<sub>50</sub> (<xref ref-type="bibr" rid="bibr34-0748233711416946">Petrikovics et al., 2010</xref>).</p>
</sec>
<sec id="section8-0748233711416946">
<title>Application of PEG conjugation</title>
<p>The PEG is the most widely used polymer for protein modification due to its lack of toxicity, the relatively simple chemistry required for its covalent binding to proteins and its commercial availability. <xref ref-type="bibr" rid="bibr1-0748233711416946">Abuchowski et al. (1977)</xref> were the first who showed that extension of circulatory residence can be achieved for bovine liver catalase by PEG conjugation. Since then several studies have demonstrated the therapeutic improvement of recombinant proteins by PEG conjugation. It is believed that PEG attachment to proteins extends their circulatory residence through interference with protein removal pathways, including kidney glomerular filtration, proteolytic degradation, as well as in active clearance via specific receptors. One of the limitations of PEG conjugation to proteins is that it may lead to loss of biological activity (<xref ref-type="bibr" rid="bibr12-0748233711416946">Chapman et al., 1999</xref>; <xref ref-type="bibr" rid="bibr47-0748233711416946">Veronese et al., 1996</xref>).</p>
<p>It was shown that conjugation of PEG chains to recombinant human AChE results in the extension of its residence time in the circulation in mice and monkey (<xref ref-type="bibr" rid="bibr14-0748233711416946">Cohen et al., 2001</xref>; <xref ref-type="bibr" rid="bibr22-0748233711416946">Kronman et al., 2010</xref>). By profiling the pharmacokinetic behavior of an array of well-defined hypolysine human mutant AChE molecules following PEGylation, it was also determined that the duration of these enzyme forms in the circulation of <italic>Rhesus macacus</italic> correlates with their number of appended PEG moieties and is influenced by the actual location of the PEG chains at the molecule surface as well (<xref ref-type="bibr" rid="bibr22-0748233711416946">Kronman et al., 2010</xref>).</p>
<p>In a recent research of <xref ref-type="bibr" rid="bibr30-0748233711416946">Novikov et al. (2010)</xref>, OPH was conjugated with linear and branched methyl-PEO(n)-NHS (N-hydroxysuccinimide) esters of relatively small molecular mass from 333 to 2,420 Da. The effects of PEGylation on the biochemical and pharmacological characteristics of OPH were examined. PEGylated OPH displayed a decreased maximal catalytic rate, though substantial activity was maintained against two tested substrates: up to 30% with PO and up to 50–60% with demeton-S. The enzyme conjugates revealed a significant improvement in pharmacokinetic properties in animal studies. The clearance from a guinea pig’s blood stream significantly decreased relative to unmodified OPH, resulting in an increase of residence time and systemic availability. Evaluation of the humoral immune response indicated that the branched PEG-OPH conjugate significantly reduced the production of anti-OPH antibodies, compared to the unmodified enzyme (<xref ref-type="bibr" rid="bibr30-0748233711416946">Novikov et al., 2010</xref>).</p>
</sec>
<sec id="section9-0748233711416946">
<title>Conclusions</title>
<p>These experiments and results are confirming that the approach of utilizing externally administered, encapsulated, metabolizing enzymes may have broad implications in drug antidotal therapy. The application of this approach has been successfully tested in animal models for OP and CN antagonism.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure" id="fn1-0748233711416946">
<p>This work was supported by the János Bolyai Research Scholarship of the Hungarian Academy of Sciences (M. B.) and the Robert A. Welch Foundation (x-0011) at Sam Houston State University (Huntsville, TX, USA). Many thanks for the support by the CounterACT Program, National Institutes of Health Office of the Director, and the National Institute of Environmental Health Sciences, Grant #UO1 NS058035, and NIH:NIAID/USAMRICD Interagency Agreements (W911NF-07-D-0001), the USAMRICD under the auspices of the U.S. Army Research Office Scientific Services Program administered by Battelle (Delivery order 0557, Contract No TCN 08284).</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0748233711416946">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abuchowski</surname>
<given-names>A</given-names>
</name>
<name>
<surname>McCoy</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Palczuk</surname>
<given-names>NC</given-names>
</name>
<name>
<surname>Van Es</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Davis</surname>
<given-names>FF</given-names>
</name>
</person-group> (<year>1977</year>) <article-title>Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase</article-title>. <source>Journal of Biological Chemistry</source>
<volume>252</volume>
(<issue>11</issue>): <fpage>3582</fpage>–<lpage>3586</lpage>.</citation>
</ref>
<ref id="bibr2-0748233711416946">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ashani</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Rothshild</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Segall</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Levanon</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Raveh</surname>
<given-names>L</given-names>
</name>
</person-group> (<year>1991</year>) <article-title>Prophylaxis against organophosphate poisoning by an enzyme hydrolysing organophosphorus compound in mice</article-title>. <source>Life Sciences</source>
<volume>49</volume>
(<issue>5</issue>): <fpage>367</fpage>–<lpage>374</lpage>.</citation>
</ref>
<ref id="bibr3-0748233711416946">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bangham</surname>
<given-names>AD</given-names>
</name>
</person-group> (<year>1963</year>) <article-title>Physical structure and behaviour of lipids and lipid enzymes</article-title>. <source>Advances Lipid Research</source>
<volume>1</volume>: <fpage>65</fpage>–<lpage>104</lpage>.</citation>
</ref>
<ref id="bibr4-0748233711416946">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barenholz</surname>
<given-names>Y</given-names>
</name>
</person-group> (<year>2001</year>) <article-title>Liposome application: problems and prospects</article-title>. <source>Current Opinion in Colloid and Interface Science</source>
<volume>6</volume>: <fpage>66</fpage>–<lpage>77</lpage>.</citation>
</ref>
<ref id="bibr5-0748233711416946">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baskin</surname>
<given-names>SI</given-names>
</name>
<name>
<surname>Porter</surname>
<given-names>DW</given-names>
</name>
<name>
<surname>Rockwood</surname>
<given-names>GA</given-names>
</name>
<name>
<surname>Romano</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Patel</surname>
<given-names>HC</given-names>
</name>
<name>
<surname>Kiser</surname>
<given-names>RC</given-names>
</name>
<etal/>
</person-group> (<year>1999</year>) <article-title>In vitro and <italic>in vivo</italic> comparison of sulfur donors as antidotes to acute cyanide intoxication</article-title>. <source>Journal of Applied Toxicology</source>
<volume>19</volume>
(<issue>3</issue>): <fpage>173</fpage>–<lpage>183</lpage>.</citation>
</ref>
<ref id="bibr6-0748233711416946">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bordo</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Deriu</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Colnaghi</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Carpen</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Pagani</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Bolognesi</surname>
<given-names>M</given-names>
</name>
</person-group> (<year>2000</year>) <article-title>The crystal structure of sulfurtransferase from Azobacter vinelandii highlights the evolutionary relationship between the rhodanese and phosphate enzyme families</article-title>. <source>Journal of Molecular Biology</source>
<volume>298</volume>
(<issue>4</issue>): <fpage>691</fpage>–<lpage>704</lpage>.</citation>
</ref>
<ref id="bibr7-0748233711416946">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Broomfield</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Maxwell</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Selana</surname>
<given-names>RP</given-names>
</name>
<name>
<surname>Castro</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Finger</surname>
<given-names>AV</given-names>
</name>
<name>
<surname>Lenz</surname>
<given-names>DE</given-names>
</name>
</person-group> (<year>1991</year>) <article-title>Protection by butyrylcholinestarase against organophosphorus poisoning in nonhuman primates</article-title>. <source>Journal of Pharmacology and Experimental Therapeutics</source>
<volume>259</volume>
(<issue>2</issue>): <fpage>633</fpage>–<lpage>638</lpage>.</citation>
</ref>
<ref id="bibr8-0748233711416946">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Broomfield</surname>
<given-names>CA</given-names>
</name>
</person-group> (<year>1992</year>) <article-title>A purified recombinant phosphotriesterase protects mice against soman</article-title>. <source>Pharmacology and Toxicology</source>
<volume>70</volume>
(<issue>1</issue>): <fpage>65</fpage>–<lpage>66</lpage>.</citation>
</ref>
<ref id="bibr9-0748233711416946">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Budai</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Chapela</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Gróf</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Zimmer</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Wales</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Wild</surname>
<given-names>JR</given-names>
</name>
<etal/>
</person-group> (<year>2009</year>). <article-title>Physico-chemical characterization of stealth liposomes encapsulating an organophosphate hydrolyzing enzyme</article-title>. <source>Journal of Lipid Research</source>
<volume>19</volume>
(<issue>2</issue>): <fpage>163</fpage>–<lpage>168</lpage>.</citation>
</ref>
<ref id="bibr10-0748233711416946">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cannon</surname>
<given-names>EP</given-names>
</name>
<name>
<surname>Leung</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Hawkins</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Petrikovics</surname>
<given-names>I</given-names>
</name>
<name>
<surname>DeLoach</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Way</surname>
<given-names>JL</given-names>
</name>
</person-group> (<year>1994</year>) <article-title>Antagonism of cyanide intoxication with murine carrier erythrocytes containing bovine rhodanese and sodium thiosulfate</article-title>. <source>Journal of Toxicology and Environmental Health</source>
<volume>41</volume>
(<issue>3</issue>): <fpage>267</fpage>–<lpage>274</lpage>.</citation>
</ref>
<ref id="bibr11-0748233711416946">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cerasoli</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Griffith</surname>
<given-names>EM</given-names>
</name>
<name>
<surname>Doctor</surname>
<given-names>BP</given-names>
</name>
<name>
<surname>Saxena</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Federko</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Greigh</surname>
<given-names>NH</given-names>
</name>
<etal/>
</person-group> (<year>2005</year>) <article-title>In vitro and <italic>in vivo</italic> characterization of recombinant human butyrylcholinesterase (Protexia) as a potential nerve agent bioscavenger</article-title>. <source>Chemico-Biological Interaction</source>
<volume>157</volume>: <fpage>363</fpage>–<lpage>365</lpage>.</citation>
</ref>
<ref id="bibr12-0748233711416946">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chapman</surname>
<given-names>AP</given-names>
</name>
<name>
<surname>Antoniw</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Spitali</surname>
<given-names>M</given-names>
</name>
<name>
<surname>West</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Stephens</surname>
<given-names>S</given-names>
</name>
<name>
<surname>King</surname>
<given-names>DJ</given-names>
</name>
</person-group> (<year>1999</year>) <article-title>Therapeutic antibody fragments with prolonged <italic>in vivo</italic> half-lives</article-title>. <source>Nature Biotechnology</source>
<volume>17</volume>
(<issue>8</issue>): <fpage>780</fpage>–<lpage>783</lpage>.</citation>
</ref>
<ref id="bibr13-0748233711416946">
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Cheng</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Harvey</surname>
<given-names>SP</given-names>
</name>
<name>
<surname>DeFrank</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Petrikovics</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Rastogi</surname>
<given-names>VK</given-names>
</name>
</person-group> (<year>2004</year>) <article-title>Bacterial enzymes–potential applications for personell/casualty decontamination against G, V, and HD chemical agents</article-title>. In: <person-group person-group-type="editor">
<name>
<surname>Flora</surname>
<given-names>SJS</given-names>
</name>
<name>
<surname>Romano</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Baskin</surname>
<given-names>SI</given-names>
</name>
<name>
<surname>Sekhar</surname>
<given-names>K</given-names>
</name>
</person-group> (eds) <source>Pharmacological Perspectives of Toxic Chemicals and Their Antidotes</source>. <publisher-loc>New Delhi</publisher-loc>: <publisher-name>Narosa Publishing House</publisher-name>, <fpage>87</fpage>–<lpage>95</lpage>.</citation>
</ref>
<ref id="bibr14-0748233711416946">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cohen</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Kronman</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Chitlaru</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Ordentlich</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Velan</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Shafferman</surname>
<given-names>A</given-names>
</name>
</person-group> (<year>2001</year>) <article-title>Effect of chemical modification of recombinant human acetylcholinesterase by polyethylene glycol on its circulatory longevity</article-title>. <source>Biochemical Journal</source>
<volume>357</volume>
(<issue>pt 3</issue>): <fpage>795</fpage>–<lpage>802</lpage>.</citation>
</ref>
<ref id="bibr15-0748233711416946">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Deakin</surname>
<given-names>SP</given-names>
</name>
<name>
<surname>James</surname>
<given-names>RW</given-names>
</name>
</person-group> (<year>2004</year>) <article-title>Genetic environmental factors modulating serum concentrations and activities of the antioxidant enzyme paraoxonase-1</article-title>. <source>Clinical Science</source>
<volume>107</volume>
(<issue>5</issue>): <fpage>435</fpage>–<lpage>437</lpage>.</citation>
</ref>
<ref id="bibr16-0748233711416946">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dooley</surname>
<given-names>TP</given-names>
</name>
<name>
<surname>Nair</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Garcia</surname>
<given-names>RT</given-names>
</name>
<name>
<surname>Courtney</surname>
<given-names>BC</given-names>
</name>
</person-group> (<year>1995</year>) <article-title>Mouse rhodanese gene (Tst):cDNA cloning, sequencing, and recombinant protein expression</article-title>. <source>Biochemical and Biophysical Research Communication</source>
<volume>216</volume>
(<issue>3</issue>): <fpage>1101</fpage>–<lpage>1109</lpage>.</citation>
</ref>
<ref id="bibr17-0748233711416946">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Draganov</surname>
<given-names>DI</given-names>
</name>
<name>
<surname>Teiber</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Speelman</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Osawa</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Sunahara</surname>
<given-names>R</given-names>
</name>
<name>
<surname>La Du</surname>
<given-names>BN</given-names>
</name>
</person-group> (<year>2005</year>) <article-title>Human paraoxonases (PON1, PON2, PON3) are lactonases with overlapping and distinct substrate specificities</article-title>. <source>Journal of Lipid Research</source>
<volume>46</volume>
(<issue>6</issue>): <fpage>1239</fpage>–<lpage>1247</lpage>.</citation>
</ref>
<ref id="bibr18-0748233711416946">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Frankenberg</surname>
<given-names>L</given-names>
</name>
</person-group> (<year>1980</year>) <article-title>Enzyme therapy in cyanide poisoning: effect of rhodanese and sulfur compounds</article-title>. <source>Archives of Toxicology</source>
<volume>45</volume>
(<issue>4</issue>): <fpage>315</fpage>–<lpage>323</lpage>.</citation>
</ref>
<ref id="bibr19-0748233711416946">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Furlong</surname>
<given-names>CE</given-names>
</name>
<name>
<surname>Richter</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Chapline</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Crabb</surname>
<given-names>JW</given-names>
</name>
</person-group> (<year>1991</year>) <article-title>Purification of rabbit and human serum paraoxonase</article-title>. <source>Biochemistry</source>
<volume>30</volume>
(<issue>42</issue>): <fpage>10133</fpage>–<lpage>10140</lpage>.</citation>
</ref>
<ref id="bibr20-0748233711416946">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname>
<given-names>Y-J</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Baldassarre</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Lazaris</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Leduc</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group> (<year>2007</year>) <article-title>Recombinant human butyrylcholinesterase from milk of transgenic animals to protect against organophosphate poisoning</article-title>. <source>Proceedings of the National Academy of Sciences</source>
<volume>104</volume>
(<issue>34</issue>): <fpage>13603</fpage>–<lpage>13608</lpage>.</citation>
</ref>
<ref id="bibr21-0748233711416946">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ihler</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Glew</surname>
<given-names>RH</given-names>
</name>
<name>
<surname>Schnure</surname>
<given-names>FM</given-names>
</name>
</person-group> (<year>1973</year>) <article-title>Enzyme loading erythrocytes</article-title>. <source>Proceedings of the National Academy of Sciences</source>
<volume>70</volume>
(<issue>9</issue>): <fpage>2663</fpage>–<lpage>2666</lpage>.</citation>
</ref>
<ref id="bibr22-0748233711416946">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kronman</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Cohen</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Mazor</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Ordentlich</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Raveh</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Velan</surname>
<given-names>B</given-names>
</name>
<etal/>
</person-group> (<year>2010</year>) <article-title>Next generation OP-bioscavengers: a circulatory long-lived 4-PEG hypolysine mutant of F338A-HuAChE with optimal pharmacokinetics and pseudo-catalytic characteristics</article-title>. <source>Chemico-Biological Interactions</source>
<volume>187</volume>
(<issue>1–3</issue>): <fpage>253</fpage>–<lpage>258</lpage>.</citation>
</ref>
<ref id="bibr23-0748233711416946">
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>La Du</surname>
<given-names>BN</given-names>
</name>
</person-group> (<year>2002</year>) <article-title>Historical considerations</article-title>. In: <person-group person-group-type="editor">
<name>
<surname>Costa</surname>
<given-names>LG</given-names>
</name>
<name>
<surname>Furlong</surname>
<given-names>CE</given-names>
</name>
</person-group> (eds) <source>Paraoxonases (PON1) in Health and Disease, Basic and Clinical Aspects</source>. <publisher-loc>Boston, MA</publisher-loc>: <publisher-name>Kluwer Academic Press</publisher-name>, <fpage>53</fpage>–<lpage>77</lpage>.</citation>
</ref>
<ref id="bibr24-0748233711416946">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lenz</surname>
<given-names>DE</given-names>
</name>
<name>
<surname>Yeung</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Sneeney</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Lumley</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Cerasoli</surname>
<given-names>DM</given-names>
</name>
</person-group> (<year>2007</year>) <article-title>Stoichiometric and catalytic scavengers as protection against nerve agent toxicity: a mini review</article-title>. <source>Toxicology</source>
<volume>233</volume>
(<issue>1–3</issue>): <fpage>31</fpage>–<lpage>39</lpage>.</citation>
</ref>
<ref id="bibr25-0748233711416946">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leung</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Cannon</surname>
<given-names>EP</given-names>
</name>
<name>
<surname>Petrikovics</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Hawkins</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Way</surname>
<given-names>JL</given-names>
</name>
</person-group> (<year>1991a</year>) <article-title>In vivo</article-title>
<article-title>studies on rhodanese encapsulation in mouse carrier erythrocytes</article-title>. <source>Toxicology and Applied Pharmacology</source>
<volume>110</volume>
(<issue>2</issue>): <fpage>268</fpage>–<lpage>274</lpage>.</citation>
</ref>
<ref id="bibr26-0748233711416946">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leung</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Davis</surname>
<given-names>RW</given-names>
</name>
<name>
<surname>Yao</surname>
<given-names>CC</given-names>
</name>
<name>
<surname>Cannon</surname>
<given-names>EP</given-names>
</name>
<name>
<surname>Way</surname>
<given-names>JL</given-names>
</name>
</person-group> (<year>1991b</year>) <article-title>Rhodanese and sodium thiosulfate encapsulated in mouse carrier erythrocytes</article-title>. <source>Fundamental and Applied Toxicology</source>
<volume>16</volume>
(<issue>3</issue>): <fpage>559</fpage>–<lpage>566</lpage>.</citation>
</ref>
<ref id="bibr27-0748233711416946">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>WW</given-names>
</name>
<name>
<surname>Costa</surname>
<given-names>LG</given-names>
</name>
<name>
<surname>Richter</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Hagen</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Shih</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Tward</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group> (<year>2000</year>) <article-title>Catalytic efficiency determines the <italic>in vivo</italic> efficacy of PON1 for detoxifying organophosphates</article-title>. <source>Pharmacogenetics</source>
<volume>10</volume>
(<issue>9</issue>): <fpage>767</fpage>–<lpage>780</lpage>.</citation>
</ref>
<ref id="bibr28-0748233711416946">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Masson</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Chatonnet</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lockridge</surname>
<given-names>O</given-names>
</name>
</person-group> (<year>1990</year>) <article-title>Evidence for a single butyrylcholinesterase gene in individuals carrying the C<sub>5</sub> plasma cholinesterase variant</article-title>. <source>FEBS Letters</source>
<volume>262</volume>
(<issue>1</issue>): <fpage>115</fpage>–<lpage>118</lpage>.</citation>
</ref>
<ref id="bibr29-0748233711416946">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>McGuinn</surname>
<given-names>WD</given-names>
</name>
<name>
<surname>Baxter</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Pei</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Petrikovics</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Cannon</surname>
<given-names>EP</given-names>
</name>
<name>
<surname>Way</surname>
<given-names>JL</given-names>
</name>
</person-group> (<year>1994</year>) <article-title>Antagonism of lethal effects of cyanide by synthetic water-soluble cobalt(III) porphyrin compound</article-title>. <source>Fundamental and Applied Toxicology</source>
<volume>23</volume>
(<issue>1</issue>): <fpage>76</fpage>–<lpage>80</lpage>.</citation>
</ref>
<ref id="bibr30-0748233711416946">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Novikov</surname>
<given-names>BN</given-names>
</name>
<name>
<surname>Grimsley</surname>
<given-names>JK</given-names>
</name>
<name>
<surname>Kern</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Wild</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Wales</surname>
<given-names>ME</given-names>
</name>
</person-group> (<year>2010</year>) <article-title>Improved pharmacokinetics and immunogenicity profile of organophosphorus hydrolase by chemical modification with polyethylene glycol</article-title>. <source>Journal of Controlled Release</source>
<volume>146</volume>
(<issue>3</issue>): <fpage>318</fpage>–<lpage>325</lpage>.</citation>
</ref>
<ref id="bibr31-0748233711416946">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Papahadjopoulos</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Allen</surname>
<given-names>TM</given-names>
</name>
<name>
<surname>Gabizon</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Mayhew</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Matthay</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>SK</given-names>
</name>
<etal/>
</person-group> (<year>1991</year>) <article-title>Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy</article-title>. <source>Proceedings of the National Academy of Sciences</source> (<publisher-loc>USA</publisher-loc>) <volume>88</volume>
(<issue>24</issue>): <fpage>11460</fpage>–<lpage>11464</lpage>.</citation>
</ref>
<ref id="bibr32-0748233711416946">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pei</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Omburo</surname>
<given-names>G</given-names>
</name>
<name>
<surname>McGuinn</surname>
<given-names>WD</given-names>
</name>
<name>
<surname>Petrikovics</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Dave</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Raushel</surname>
<given-names>FM</given-names>
</name>
<etal/>
</person-group> (<year>1994</year>) <article-title>Encapsulation of phosphotriesterase within murine erythrocytes</article-title>. <source>Toxicology and Applied Pharmacology</source>
<volume>124</volume>
(<issue>2</issue>): <fpage>296</fpage>–<lpage>301</lpage>.</citation>
</ref>
<ref id="bibr33-0748233711416946">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pei</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Petrikovics</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Way</surname>
<given-names>JL</given-names>
</name>
</person-group> (<year>1995</year>) <article-title>Antagonism of the lethal effect of paraoxone by carrier erythrocytes containing organophosphorous acid anhydrase</article-title>. <source>Fundamental and Applied Toxicology</source>
<volume>28</volume>
(<issue>2</issue>): <fpage>209</fpage>–<lpage>214</lpage>.</citation>
</ref>
<ref id="bibr34-0748233711416946">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Petrikovics</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Baskin</surname>
<given-names>SI</given-names>
</name>
<name>
<surname>Beigel</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Schapiro</surname>
<given-names>BJ</given-names>
</name>
<name>
<surname>Rockwood</surname>
<given-names>GA</given-names>
</name>
<name>
<surname>Manage</surname>
<given-names>ABW</given-names>
</name>
<etal/>
</person-group> (<year>2010</year>) <article-title>Nano-intercalated rhodanese in cyanide antagonism</article-title>. <source>Nanotoxicology</source>
<volume>4</volume>
(<issue>2</issue>): <fpage>247</fpage>–<lpage>254</lpage>.</citation>
</ref>
<ref id="bibr35-0748233711416946">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Petrikovics</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Budai</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Baskin</surname>
<given-names>SI</given-names>
</name>
<name>
<surname>Rockwood</surname>
<given-names>GA</given-names>
</name>
<name>
<surname>Childress</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Budai</surname>
<given-names>L</given-names>
</name>
<etal/>
</person-group> (<year>2009</year>) <article-title>Characterization of liposomal vesicles encapsulating rhodanese for cyanide antagonism</article-title>. <source>Drug Delivery</source>
<volume>16</volume>
(<issue>6</issue>): <fpage>312</fpage>–<lpage>319</lpage>.</citation>
</ref>
<ref id="bibr36-0748233711416946">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Petrikovics</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Cannon</surname>
<given-names>EP</given-names>
</name>
<name>
<surname>McGuinn</surname>
<given-names>WD</given-names>
</name>
<name>
<surname>Pei</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Way</surname>
<given-names>JL</given-names>
</name>
</person-group> (<year>1995</year>) <article-title>Cyanide antagonism with organic thiosulfonates and carrier red blood cells containing rhodanese</article-title>. <source>Fundamental and Applied Toxicology</source>
<volume>24</volume>
(<issue>1</issue>): <fpage>1</fpage>–<lpage>8</lpage>.</citation>
</ref>
<ref id="bibr37-0748233711416946">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Petrikovics</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>TC</given-names>
</name>
<name>
<surname>Papahadjopoulos</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Hong</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Yin</surname>
<given-names>R</given-names>
</name>
<name>
<surname>DeFrank</surname>
<given-names>JJ</given-names>
</name>
<etal/>
</person-group> (<year>2000a</year>). <article-title>Long circulating liposomes encapsulating organophosphorus acid anhydrolase in diisopropylfluorophosphate antagonism</article-title>. <source>Toxicological Sciences</source>
<volume>57</volume>
(<issue>1</issue>): <fpage>16</fpage>–<lpage>21</lpage>.</citation>
</ref>
<ref id="bibr38-0748233711416946">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Petrikovics</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Hong</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Omburo</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>QZ</given-names>
</name>
<name>
<surname>Pei</surname>
<given-names>L</given-names>
</name>
<name>
<surname>McGuinn</surname>
<given-names>WD</given-names>
</name>
<etal/>
</person-group> (<year>1999</year>) <article-title>Antagonism of paraoxon intoxication by recombinant phosphotriesterase encapsulated within sterically stabilized liposomes</article-title>. <source>Toxicology and Applied Pharmacology</source>
<volume>156</volume>
(<issue>1</issue>): <fpage>56</fpage>–<lpage>63</lpage>.</citation>
</ref>
<ref id="bibr39-0748233711416946">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Petrikovics</surname>
<given-names>I</given-names>
</name>
<name>
<surname>McGuinn</surname>
<given-names>WD</given-names>
</name>
<name>
<surname>Cannon</surname>
<given-names>EP</given-names>
</name>
<name>
<surname>Pei</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Way</surname>
<given-names>JL</given-names>
</name>
</person-group> (<year>1994</year>) <article-title>Encapsulation of rhodanese and organic thiosulfonates by mouse erythrocytes</article-title>. <source>Fundamental and Applied Toxicology</source>
<volume>23</volume>
(<issue>1</issue>): <fpage>70</fpage>–<lpage>75</lpage>.</citation>
</ref>
<ref id="bibr40-0748233711416946">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Petrikovics</surname>
<given-names>I</given-names>
</name>
<name>
<surname>McGuinn</surname>
<given-names>WD</given-names>
</name>
<name>
<surname>Sylvester</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Yuzapavik</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Way</surname>
<given-names>JL</given-names>
</name>
<etal/>
</person-group> (<year>2000b</year>) <article-title>In vitro studies on sterically stabilized liposomes (sl) as enzyme carriers in organophosphorus (op) antagonism</article-title>. <source>Drug Delivery</source>
<volume>7</volume>
(<issue>2</issue>): <fpage>83</fpage>–<lpage>89</lpage>.</citation>
</ref>
<ref id="bibr41-0748233711416946">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Petrikovics</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Wales</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Jaszberenyi</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Budai</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Baskin</surname>
<given-names>SI</given-names>
</name>
<name>
<surname>Szilasi</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group> (<year>2007</year>) <article-title>Enzyme-based intravascular defense against organophosphorus neurotoxins: Synergism of dendritic-enzyme complexes with 2-PAM and atropine</article-title>. <source>Nanotoxicology</source>
<volume>1</volume>
(<issue>2</issue>): <fpage>85</fpage>–<lpage>92</lpage>.</citation>
</ref>
<ref id="bibr42-0748233711416946">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Raveh</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Grauer</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Grunwald</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Cohen</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Ashani</surname>
<given-names>Y</given-names>
</name>
</person-group> (<year>1997</year>) <article-title>The stoichiometry of protection against soman and VX toxicity in monkeys pre-treated with human butyrylcholinestrase</article-title>. <source>Toxicology and Applied Pharmacology</source>
<volume>145</volume>
(<issue>1</issue>): <fpage>43</fpage>–<lpage>53</lpage>.</citation>
</ref>
<ref id="bibr43-0748233711416946">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saidu</surname>
<given-names>Y</given-names>
</name>
</person-group> (<year>2004</year>) <article-title>Physicochemical features of rhodanese: a review</article-title>. <source>African Journal of Biotechnology</source>
<volume>3</volume>
(<issue>4</issue>): <fpage>370</fpage>–<lpage>374</lpage>.</citation>
</ref>
<ref id="bibr44-0748233711416946">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sanan</surname>
<given-names>TT</given-names>
</name>
<name>
<surname>Sivaramakrishnan</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Beck</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Tao</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Hayes</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Otto</surname>
<given-names>TC</given-names>
</name>
<etal/>
</person-group> (<year>2010</year>) <article-title>Computational modeling of human paraoxonases-1: preparation of protein models, binding studies, and mechanistic insights</article-title>. <source>Journal of Physical Organic Chemistry</source>
<volume>23</volume>
(<issue>4</issue>): <fpage>357</fpage>–<lpage>369</lpage>.</citation>
</ref>
<ref id="bibr45-0748233711416946">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tomalia</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Baker</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Dewald</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hall</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kallos</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group> (<year>1985</year>) <article-title>A new class of polymers-starburst-dendritic macromolecules</article-title>. <source>Polymer Journal</source>
<volume>17</volume>
(<issue>1</issue>): <fpage>117</fpage>–<lpage>132</lpage>.</citation>
</ref>
<ref id="bibr46-0748233711416946">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tomalia</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Esfand</surname>
<given-names>R</given-names>
</name>
</person-group> (<year>1997</year>) <article-title>Dendrons, dendrimers and dendrigrafts</article-title>. <source>Chemistry and Industry</source>
<volume>11</volume>: <fpage>416</fpage>–<lpage>420</lpage>.</citation>
</ref>
<ref id="bibr47-0748233711416946">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Veronese</surname>
<given-names>FM</given-names>
</name>
<name>
<surname>Monfardini</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Caliceti</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Schiavon</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Scrawen</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Beer</surname>
<given-names>D</given-names>
</name>
</person-group> (<year>1996</year>) <article-title>Improvement of pharmacokinetic, immunological and stability properties of asparaginase by conjugation to linear and branched monomethoxy poly(ethyleneglycol)</article-title>. <source>Journal of Controlled Release</source>
<volume>40</volume>
(<issue>3</issue>): <fpage>199</fpage>–<lpage>209</lpage>.</citation>
</ref>
<ref id="bibr48-0748233711416946">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Way</surname>
<given-names>JL</given-names>
</name>
</person-group> (<year>1983</year>) <article-title>Cyanide antagonism</article-title>. <source>Fundamental and Applied Toxicology</source>
<volume>3</volume>
(<issue>5</issue>): <fpage>383</fpage>–<lpage>386</lpage>.</citation>
</ref>
<ref id="bibr49-0748233711416946">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Way</surname>
<given-names>JL</given-names>
</name>
</person-group> (<year>1984</year>) <article-title>Mechanism of cyanide intoxication and its antagonism</article-title>. <source>Annual Review of Pharmacology and Toxicology</source>
<volume>24</volume>: <fpage>451</fpage>–<lpage>481</lpage>.</citation>
</ref>
<ref id="bibr50-0748233711416946">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Way</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Cannon</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Leung</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Davis</surname>
<given-names>R</given-names>
</name>
<name>
<surname>McGuinn</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Yao</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group> (<year>1991</year>) <article-title>Antagonism of cyanide intoxication with rhodanese encapsulated within resealed erythrocytes</article-title>. <source>Advances in the Bioscience</source>
<volume>81</volume>: <fpage>207</fpage>–<lpage>211</lpage>.</citation>
</ref>
<ref id="bibr51-0748233711416946">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Way</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Leung</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Ray</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Sounder</surname>
<given-names>C</given-names>
</name>
</person-group> (<year>1985</year>) <article-title>Erythrocyte-encapsulated thiosulfate sulfurtransferase</article-title>. <source>Bibliotheca Haematoligica</source>
<volume>51</volume>: <fpage>75</fpage>–<lpage>81</lpage>.</citation>
</ref>
<ref id="bibr52-0748233711416946">
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Way</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Pei</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Petrikovics</surname>
<given-names>I</given-names>
</name>
<name>
<surname>McGuinn</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Tamulinas</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>QZ</given-names>
</name>
<etal/>
</person-group> (<year>1997</year>) <article-title>Organophosphorus antagonism by resealed erythocytes containing recombinant paraoxonase</article-title>. In: <person-group person-group-type="editor">
<name>
<surname>Sprandel</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Way</surname>
<given-names>JL</given-names>
</name>
</person-group> (eds) <source>Erythrocytes as Drug Carriers in Medicine</source>. <publisher-loc>New York, NY</publisher-loc>: <publisher-name>Plenum Press</publisher-name>, <fpage>89</fpage>–<lpage>92</lpage>.</citation>
</ref>
<ref id="bibr53-0748233711416946">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xia</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Qin</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Durst</surname>
<given-names>HD</given-names>
</name>
<name>
<surname>Yin</surname>
<given-names>R</given-names>
</name>
</person-group> (<year>2002</year>) <article-title>Light scattering study of the self-association behavior of long chain branched poly(2-ethyloxazoline) in solvents</article-title>. <source>Langmuir</source>
<volume>18</volume>
(<issue>22</issue>): <fpage>8302</fpage>–<lpage>8308</lpage>.</citation>
</ref>
<ref id="bibr54-0748233711416946">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yin</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Qin</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Tomalia</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Kukowsky-Latallo</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Baker</surname>
<given-names>JR</given-names>
</name>
</person-group> (<year>1997</year>).
<article-title>From dendrimers to dendrigrafts. Synthesis, characterization and applications</article-title>. <source>Polymer Materials: Science and Engineering</source>
<volume>77</volume>: <fpage>206</fpage>–<lpage>207</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>